Earlier this month, Biocad obtained a marketing authorization for its rituximab biosimilar in Bolivia and Honduras. The product, USMAL, will be available to patients within months. Yet the Russian firm sees roadblocks ahead for US market entry.
Earlier this month, Biocad obtained a marketing authorization for its rituximab biosimilar in Bolivia and Honduras. The biosimilar product, which will be marketed under the trade name USMAL, will be available to patients within months.
Currently, only reference rituximab treatments (Roche’s Rituxan and MabThera) are available in the Bolivian and Honduran markets. In its official statement, Biocad says that competitive pricing for its product will effectively double the availability of rituximab in the 2 nations. The next step for Biocad’s involvement in the Latin American markets, the company says, is to launch its trastuzumab and bevacizumab biosimilars, already being marketed and distributed in other nations.
Biocad is currently registering its rituximab biosimilar in other countries in the region, and expects to have received 2 more marketing authorizations by the end of the year. The firm has already shipped the rituximab biosimilar to 7 other countries worldwide, including Kazakhstan, Vietnam, and Sri Lanka.
This latest move is a step toward even greater expansion for the Russian biotechnology company; earlier this year, Biocad signaled its intentions to enter the European market through establishing a partnership in Finland. Biocad plans to invest €25 million ($28 million) in Finland’s Turku region over the next 7 years as it continues to develop products for the European market.
With such a focus on global expansion—and a deepening hunger for affordable biologics in the US—Biocad has its eye on FDA approval to gain a share of the US biologics marketplace. Yet, according to Biocad, anti-competitive practices from innovators may put such a potential US market entry in jeopardy. In 2016, Biocad filed a lawsuit against Roche in the federal court in New York, saying that the innovator had attempted to drop its prices for several reference oncology drugs in Russia (purportedly to thwart competition from Biocad’s biosimilar products) while simultaneously raising prices for the same drugs in the United States.
“While Roche and Genentech keep raising prices in the US, they engage in predatory pricing in Russia, where [they] sell such drugs at a loss—all to destroy [Biocad] and prevent it from entering the US market with cheaper biosimilars,” Biocad alleged. Roche, for its part, called the lawsuit “frivolous.”
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.